Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defactinib, Avutometinib, and Nivolumab in Anti-PD1 Refractory LKB1-Mutant Advanced Lung Adenocarcinoma
NCT06495125Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Jul 2024
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of defactinib and avutometinib in lung adenocarcinoma, sponsored by Emory University. Primary endpoint: Progression-Free Survival at 6 months. Started Jul 2024; status: recruiting.
02
Drugs
defactinibavutometinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT06495125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06495125.